Entrada Therapeutics Inc (TRDA)
12.45
+0.09
(+0.73%)
USD |
NASDAQ |
Apr 26, 16:00
12.68
+0.22
(+1.81%)
After-Hours: 20:00
Entrada Therapeutics Profit Margin (Quarterly): -22.81% for Dec. 31, 2023
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -22.81% |
| September 30, 2023 | 81.08% |
| Date | Value |
|---|---|
| June 30, 2023 | -142.7% |
| March 31, 2023 | -26.42% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-142.7%
Minimum
Jun 2023
81.08%
Maximum
Sep 2023
-27.71%
Average
-24.61%
Median
Profit Margin (Quarterly) Benchmarks
| GlycoMimetics Inc | -90.79K% |
| Lyell Immunopharma Inc | -407.2K% |
| Candel Therapeutics Inc | -- |
| Eliem Therapeutics Inc | -- |
| NovaBay Pharmaceuticals Inc | -110.2% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -2.94% |
| Return on Assets | -1.39% |
| Return on Invested Capital | -2.89% |
| Operating Margin (Quarterly) | 11.72% |
| Return on Net Operating Assets | -8.02% |